O

Oncoinvent ASA
OSE:ONCIN

Watchlist Manager
Oncoinvent ASA
OSE:ONCIN
Watchlist
Price: 0.446 NOK -1.65% Market Closed
Market Cap: 199.3m NOK

Operating Margin
Oncoinvent ASA

-2 133.2%
Current
-43 706%
Average
5.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2 133.2%
=
Operating Profit
-115.3m
/
Revenue
5.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
NO
Oncoinvent ASA
OSE:ONCIN
199.3m NOK
-2 133%
US
Eli Lilly and Co
NYSE:LLY
982.7B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
528.3B USD
27%
CH
Roche Holding AG
SIX:ROG
276B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
218.7B GBP
24%
CH
Novartis AG
SIX:NOVN
220B CHF
33%
US
Merck & Co Inc
NYSE:MRK
273.7B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
146.1B USD
29%
No Stocks Found

Oncoinvent ASA
Glance View

Market Cap
199.3m NOK
Industry
Pharmaceuticals

Oncoinvent ASA engages in the development of cancer treatment products. The company is headquartered in Oslo, Oslo and currently employs 34 full-time employees. The company went IPO on 2024-12-13. The firm is engaged in the development of alpha-emitting radiotherapeutics that provide better treatment options to cancer patients. The firm offers Radspherin, which is alpha-emitting radioactive microsphere therapy designed for the treatment of metastatic cancers in body cavities. The product candidate is a suspension of inorganic microspheres labelled with an alpha-emitting radioisotope for local administration. More specifically it consists of with calcium carbonate micro particles labelled with the radioisotope Radium-224d. The therapeutic goal is to treat residual micro metastases remaining after surgery in intracavitary surfaces and liquid without subjecting deeper regions of organs and tissues to harmful radiation doses.

ONCIN Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2 133.2%
=
Operating Profit
-115.3m
/
Revenue
5.4m
What is the Operating Margin of Oncoinvent ASA?

Based on Oncoinvent ASA's most recent financial statements, the company has Operating Margin of -2 133.2%.

Back to Top